Abivax SA

IPO

Abivax SA is a biotech company in Paris, France, founded in 2013. It has raised $1.6B across 5 rounds, most recently a $747.5M Corporate Round in 2025 (est.).

Abivax | Official Website

Headquarters
Paris
Employees
51–200
Founded
2013
Business Model
B2B
Website
abivax.com
Total Funding
$1.6B
Last Round
$747.5M Corporate RoundJan 2025
Rounds
5
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 5 funding rounds and 2 investors for this company. The full record is or through the API.

About

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is an investigational orally administered once-daily small-molecule compound that enhances the expression of miR-124, a naturally occurring microRNA that plays a critical role in regulating the immune response. Obefazimod is currently in Phase 3 clinical trials (ABTECT program) for the treatment of moderately to severely active ulcerative colitis, with additional clinical programs in Crohn's disease and other inflammatory conditions. Abivax is listed on Nasdaq (ABVX) and Euronext Paris.

Summary

It lists 51–200 employees. It has raised $1.6B in total across 5 rounds, most recently a $747.5M Corporate Round in 2025 (est.). Investors include TCGX and Sofinnova Partners.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
Corporate RoundCorporate Round2025 (est.)
$747.5M

Sign up to see all 7 events

Funding: Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Abivax SA on Indexed.vc
<a href="https://indexed.vc/companies/abivax-sa"><img src="https://indexed.vc/api/badge/company/abivax-sa" alt="Abivax SA on Indexed.vc" width="260" height="76" /></a>